Triple threat: new combo aims to tackle tough breast cancer
NCT ID NCT06889688
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a combination of three drugs—camrelizumab, apatinib, and eribulin—works better than standard chemotherapy for advanced triple-negative breast cancer. The study will enroll 246 women aged 18 to 70. Researchers will measure how long the cancer stays under control and overall survival, while also checking side effects and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab, apatinib, and eribulin
- What this could lead to
- If successful, this combination could offer a new, more effective treatment option for advanced triple-negative breast cancer, potentially extending life and improving quality of life.
- What could go wrong
- This is a Phase 3 trial, but the combination may cause more side effects than standard chemo, and it's not yet proven to work better. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE IV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Changhai Hospital of Shanghai
RECRUITINGShanghai, China
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, China
-
The Affiliated Hospital of Guizhou Medical University
RECRUITINGGuiyang, Guizhou, China
-
The Central Hospital Of Yong Zhou
RECRUITINGYongzhou, Hunan, China
-
Wuhan Union Hospital of China
NOT_YET_RECRUITINGWuhan, Hubei, China
-
Xiangya Hospital of Central South University
NOT_YET_RECRUITINGChangsha, Hunan, China
-
Yichang Central People's Hospital
RECRUITINGYichang, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?